Photo by satheeshsankaran from unsplash
Abstract Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase… Click to show full abstract
Abstract Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.
Keywords:
risks ruxolitinib;
ruxolitinib stat1;
stat1 gain;
gain function;
function associated
Journal Title: Open Forum Infectious Diseases
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Open Forum Infectious Diseases
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!